Serge Belanger's Stock Ratings

Needham Analyst

Serge Belanger is an analyst at Needham. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 01/21/2025

Overall Average Return

6.38%

Smart Score

62.5%

Overall Average Return Percentile

49th

Number of Ratings

357
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

6 Analysts Assess Pacira BioSciences: What You Need To Know
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation.
Breaking Down Liquidia: 4 Analysts Share Their Views
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
Where NewAmsterdam Pharma Stands With Analysts
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
Decoding 6 Analyst Evaluations For Pacira BioSciences
The Analyst Landscape: 11 Takes On Liquidia
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved